1610954-85-2

Upstream product

• 1500921-65-2 (5-bromo-2-methylphenyl)(4-chlorophenyl)methanone 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 21900-41-4 5-bromo-2-methylbenzoyl?chloride 
• 842135-03-9 5-bromo-N-methoxy-N,2-dimethylbenzamide 

Downstream Products

• 1610955-63-9 (2S,3S,4R,5S,6R)-2-(3-(4-(4-methoxy-4-oxobutyl)benzyl)-4-methylphenyl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610954-87-4 (3aS,5S,6R,6aS)-5-((S)-(3-(4-chlorobenzyl)-4-methylphenyl)-(hydroxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 
• 1610954-90-9 (2S,3S,4R,5S,6R)-2-(3-(4-chlorobenzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610954-91-0 (2S,3S,4R,5S,6R)-2-(3-(4-((E)-4-methoxy-4-oxobut-1-en-1-yl)-benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610954-92-1 (2S,3S,4R,5S,6R)-2-(3-(4-(4-methoxy-4-oxobutyl)benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610954-93-2 4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanoic acid 
• 1610954-94-3 N-(1-amino-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide 
• 1610955-01-5 (2S,3S,4R,5S,6R)-2-(3-(4-(5-aminopentyl)benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-04-8 2-methyl-2-(3-(5-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)pentyl)ureido)propanamide 

Relevant academic research and scientific papers

Application of medicine containing sodium-glucose co-transporter 1 inhibitor

The invention relates to a sodium-glucose co-transporter 1 (SGTL1) inhibitor, a synthetic method of medicine containing a composition and application of the medicine in treating metabolic diseases, and particularly type 2 diabetes.

Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) Inhibitor restricted to the intestinal lumen, for the treatment of diabetes

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodiumdependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1

Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula (I): the various substituents of which are defined herein.